AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal
Completed
- Conditions
- Asthma
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 842
- Registration Number
- NCT05169619
- Locations
- 🇵🇹
Research Site, Évora, Portugal
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Phase 3
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1132
- Registration Number
- NCT05166889
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants
Phase 1
Completed
- Conditions
- Corona Virus Disease
- Interventions
- Biological: AZD8895 (cell pool material)Biological: AZD8895 (clonal cell line material)Biological: AZD1061 (cell pool material)Biological: AZD1061 (clonal cell line material)
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 224
- Registration Number
- NCT05166421
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 679
- Registration Number
- NCT05160974
- Locations
- 🇰🇷
Research Site, Yongin-si, Korea, Republic of
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
Phase 3
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1172
- Registration Number
- NCT05158387
- Locations
- 🇬🇧
Research Site, Shipley, United Kingdom
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
Phase 1
Completed
- Conditions
- SafetyTolerabilityPharmacokineticsHealthy Participants
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT05143905
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)
Active, not recruiting
- Conditions
- Lupus Erythematosus, Systemic
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1620
- Registration Number
- NCT05141201
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
CLL Therapy Approaches in Russia
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6000
- Registration Number
- NCT05140369
- Locations
- 🇷🇺
Research site, Vologda, Russian Federation
🇷🇺Research Site, Yaroslavl, Russian Federation
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL
Phase 2
Completed
- Conditions
- Relapsed/Refractory Peripheral T-cell LymphomaRelapsed/Refractory Classical Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 52
- Registration Number
- NCT05140382
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 360
- Registration Number
- NCT05138133
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath